Medpace Holdings, Inc. (MEDP)

NASDAQ • Healthcare

$599.47

+$1.38 (+0.2%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$593.03

Day Range$587.39 - $609.75

Avg. Volume (3M)255.4K

Market Cap$16.7B

P/E Ratio34.5

52 Week Range

$373$677.9

Next EarningsIn 17 daysOct 21, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$707.3M100%

Gross Profitminus cost of goods$201.6M29%

Operating Incomeminus R&D and overhead$146.8M21%

Net Incomeminus taxes and the rest$121.3M17%

In plain terms: out of every $100 in revenue, Medpace Holdings, Inc. keeps $17 as net profit.

Fundamentals & Financials

Revenue (TTM)

$2.7B

Net Income (TTM)

$491.5M

EPS (TTM)

$17.39

ROA (TTM)

23.89%

Current Ratio

0.73

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+4.0%Q3 2025$3.1

+9.3%Q4 2025$3.86

+11.5%Q1 2026$4.67

+9.2%Q2 2026$4.28

+6.8%Q3 2026$4.25

Oct 21

in 17 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +6.8%

Medpace Holdings topped consensus on both revenue and EPS in the second fiscal quarter of 2026, reported July 22, with revenue of $707.3 million against a $689.5 million estimate, +2.6%, and EPS of $4.25 versus $3.98, +6.8%. That came as revenue rose 17.2% to about $707.3 million from $603.3 million a year earlier, net income climbed 34.5% to about $121.4 million from $90.3 million, and EPS was up 37.1% from $3.10. Gross margin was near 29% and operating margin about 21%, with operating income around $146.8 million. Operating cash flow was about $162.0 million, and the company repurchased about $294.8 million of stock. For the next period, consensus calls for EPS of $4.39 on revenue of $714.3 million.

Next report — what to expect

Medpace Holdings, Inc. (MEDP) reports next on October 21, 2026. Wall Street is looking for EPS of $4.41 on revenue of $714.3 million. For trailing context, revenue grew +17.2% year over year last quarter. Medpace has beaten EPS in 8 of its 8 most recent quarters.

View full earnings history

About Medpace Holdings, Inc.

Medpace Holdings, Inc. provides outsourced clinical development and research services to drug, biotechnology, and medical-device companies, pairing trial management with laboratory and data capabilities across the healthcare research and diagnostics field. Listed on the NASDAQ as MEDP, the company recorded $2.5 billion of revenue in FY2025.

Name

Medpace Holdings, Inc.

CEO

August James Troendle

Website

www.medpace.com

Industry

Healthcare

Year Founded

1992

Employees

6,500

Today's Snapshot

AI-generated

The day ended with MEDP slightly higher at 599.47, in line with a flat sector.

Trading Volume

Above 10d avg 263.0K

303K

vs S&P 500 Today

Underperforming Market

-0.55%

Updated: October 2, 2026 at 20:18 UTC

Technical Indicators

3 Buy3 Neutral2 Sell

MEDP carries a marginal buy signal as the share price near $599 remains above the 200-day average in the mid-$520s, supporting a longer-term bullish bias, while shorter-term moving averages sit higher and reflect recent weakness. MACD is positive and on-balance volume is firmly positive, lending support to the buy stance even though near-term momentum is soft and RSI is neutral. ADX is moderate and volatility is contained with an ATR around $16–17. Technical takeaway: Buy — long-term trend and positive volume favor the upside despite short-term pressure.

All signals